Ozempic and Wegovy have been increasingly used by non-diabetics for weight loss in the U.S., raising concerns about the potential risks of thyroid cancer affecting a much larger portion of the population.
Some compounded versions of Ozempic and Wegovy use salt forms of the active ingredient which have not been tested or approved by the agency.
A leading hair loss expert warns that Ozempic problems may lead to androgenic alopecia, a progressive and permanent form of pattern baldness.
Some users say the Ozempic and Wegovy hair loss does not appear to be linked to weight loss caused by the diabetes drugs
Some patients have filed lawsuits indicating manufacturers failed to warn about the genital infection risk of the popular class of diabetes drugs.
Higher doses and longer durations of use both appeared to increase the gallbladder risks, researchers warn.
Four out of 10 nursing home residents face overtreatment for diabetes, putting them at risk of dangerously low blood sugar levels.
